A rapid technology transfer encompassing science, innovation, technology, quality, and regulatory know-how, both to governments (enabling them to effectively oversee the industry and the quality of the drug products) and directly to industry stakeholders.

Robust capabilities in end-to-end project management, spanning from the initial technology transfer agreement to the establishment of comprehensive manufacturing and testing capabilities.

Investment in training the local workforce in manufacturing and testing procedures specific to vaccines and biologics, ensuring they have the essential know-how for local development, process engineering, and analytical science.

While we don't engage in construction directly, our strategic partnerships empower us to facilitate the establishment of state-of-the-art vaccines and biologics facilities that complies with EMA and US FDA quality and compliance requirements. With the help of our partners, these critical resources are brought to operational readiness in an impressively short timeframe.